cytosine has been researched along with Granulocytic Leukemia, Chronic in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia." | 9.10 | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. ( Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA, 2002) |
| "To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia." | 9.09 | Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. ( Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA, 2001) |
| "Over an eight-month period from October 1997 to May 1998, four patients who had received bone marrow transplant (BMT) from unrelated donor presented with severe mucosal cutaneous infections involving acyclovir resistant herpes simplex virus 1 (HSV-1)." | 7.71 | Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Bordigoni, P; Carret, AS; Corsaro, D; Dauendorffer, JN; Edert, D; Le Faou, A; Venard, V, 2001) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 7.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5." | 5.10 | Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. ( Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA, 2003) |
| "To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia." | 5.10 | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. ( Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA, 2002) |
| "To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia." | 5.09 | Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. ( Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA, 2001) |
| " We report successful BCV use in management of disseminated acyclovir- and cidofovir-resistant varicella zoster virus in an immunocompromised hematopoietic stem cell transplant patient with chronic graft-versus-host disease who was intolerant to foscarnet." | 3.83 | Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. ( Hartline, CB; Larson, RA; Mommeja-Marin, H; Mullane, KM; Nuss, C; Prichard, MN; Ridgeway, J; Theusch, J, 2016) |
| "Over an eight-month period from October 1997 to May 1998, four patients who had received bone marrow transplant (BMT) from unrelated donor presented with severe mucosal cutaneous infections involving acyclovir resistant herpes simplex virus 1 (HSV-1)." | 3.71 | Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation. ( Bordigoni, P; Carret, AS; Corsaro, D; Dauendorffer, JN; Edert, D; Le Faou, A; Venard, V, 2001) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 3.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "The K562 human chronic myelogenous leukemia (CML) cell line has attained widespread use as a model for studying hematologic malignancy and erythroid differentiation." | 1.29 | Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. ( Ferrell, RE; Law, JC; Leder, GH; Ritke, MK; Yalowich, JC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mullane, KM | 1 |
| Nuss, C | 1 |
| Ridgeway, J | 1 |
| Prichard, MN | 1 |
| Hartline, CB | 1 |
| Theusch, J | 1 |
| Mommeja-Marin, H | 1 |
| Larson, RA | 2 |
| Cortes, J | 2 |
| Giles, F | 1 |
| Giles, FJ | 5 |
| Faderl, S | 2 |
| Thomas, DA | 3 |
| Cortes, JE | 4 |
| Garcia-Manero, G | 2 |
| Douer, D | 1 |
| Levine, AM | 1 |
| Koller, CA | 1 |
| Jeha, SS | 1 |
| O'Brien, SM | 3 |
| Estey, EH | 1 |
| Kantarjian, HM | 4 |
| Feldman, EJ | 1 |
| Roboz, GJ | 1 |
| Mamus, SW | 1 |
| Verstovsek, S | 2 |
| Talpaz, M | 1 |
| Beran, M | 3 |
| Albitar, M | 1 |
| Orsolic, N | 1 |
| Gourdeau, H | 1 |
| Golemovic, M | 1 |
| Freireich, EJ | 1 |
| Kantarjian, H | 1 |
| Snoeck, R | 1 |
| Andrei, G | 1 |
| Gérard, M | 1 |
| Silverman, A | 1 |
| Hedderman, A | 1 |
| Balzarini, J | 1 |
| Sadzot-Delvaux, C | 1 |
| Tricot, G | 1 |
| Clumeck, N | 1 |
| De Clercq, E | 1 |
| Law, JC | 1 |
| Ritke, MK | 1 |
| Yalowich, JC | 1 |
| Leder, GH | 1 |
| Ferrell, RE | 1 |
| Ohyashiki, JH | 1 |
| Ohyashiki, K | 1 |
| Kawakubo, K | 1 |
| Tauchi, T | 1 |
| Shimamoto, T | 1 |
| Toyama, K | 1 |
| Fajkusová, L | 1 |
| Fajkus, J | 1 |
| Polácková, K | 1 |
| Fulnecek, J | 1 |
| Dvoráková, D | 1 |
| Krahulcová, E | 1 |
| Baker, SD | 2 |
| O'Brien, S | 1 |
| Smith, TL | 1 |
| Bivins, C | 2 |
| Jolivet, J | 2 |
| Venard, V | 1 |
| Dauendorffer, JN | 1 |
| Carret, AS | 1 |
| Corsaro, D | 1 |
| Edert, D | 1 |
| Bordigoni, P | 1 |
| Le Faou, A | 1 |
| Arnulf, B | 1 |
| Chebbi, F | 1 |
| Lefrere, F | 1 |
| Ait Arkoub, Z | 1 |
| Varet, B | 1 |
| Fillet, AM | 1 |
| Miller, CB | 1 |
| Andreeff, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cytosine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
New agents in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferas | 2003 |
4 trials available for cytosine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2003 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytosine; Dioxolanes; Drug Resist | 2003 |
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Blast Crisis; Cytosine; Dioxolanes; Dose-Response | 2001 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Leukemi | 2002 |
8 other studies available for cytosine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host.
Topics: Acyclovir; Adult; Antibiotic Prophylaxis; Antineoplastic Agents; Antiviral Agents; Cytosine; Drug Re | 2016 |
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Cytosine; Dioxol | 2004 |
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1994 |
Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line.
Topics: Amino Acid Sequence; Base Sequence; Blotting, Western; Cell Line; Codon; Cytosine; DNA Primers; DNA | 1993 |
The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells.
Topics: 5-Methylcytosine; Cytosine; DNA, Neoplasm; Granulocytes; Hematopoiesis; Hematopoietic Stem Cells; Hu | 1993 |
Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Topics: Base Sequence; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytosine; Dinu | 2000 |
Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Acyclovir; Adolescent; Amino Acid Substitution; Antiviral Agents; Bone Marrow Transpl | 2001 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofov | 2001 |